MedTrace Logo

Investigation of Lymph Node Biology in Kidney Cancer

NCT07038733 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-02-03

No results posted yet for this study

Summary

The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected will be used for current and future research projects involving the study of kidney cancer biology and related medical conditions. We will use this valuable resource to ask clinically relevant translational questions that pertain to biomarker discovery/validation, identification of novel therapeutic targets, and to better understand the genetic and biological basis of the various kidney cancers.

Conditions

  • Renal Cell Carcinoma (RCC)

Interventions

PROCEDURE

Peripheral Blood Sample for Immune Analysis

A peripheral blood sample will be collected at the time of surgery.

PROCEDURE

Tumor Sample for Analysis

Extra tumor which is left over following clinical diagnoses will be collected.

PROCEDURE

Adjacent non-malignant kidney for analysis

Extra normal tissue which is left over following clinical diagnoses will be collected.

PROCEDURE

Draining lymph node(s) for analysis

Draining lymph nodes which have been identified by the surgeon visually, potentially using a tracer (injection of up to 5mg of ICG into the peritumor kidney) will be collected.

PROCEDURE

Regional non-draining lymph node(s) for analysis

Regional lymph nodes which have been deemed as non-draining by the surgeon will be collected.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • David Braun, MD · Yale University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-30
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07038733 on ClinicalTrials.gov